BethAOvermoyerMD

Oncology • Boston, MA

Breast Cancer, Cancer Genetics/Cancer Risk Assessment, Hematologic Oncology

Assistant Professor of Medicine, Dana Farber Cancer Institute

Join to view full profile

Dr. Overmoyer is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Overmoyer's full profile

Already have an account?

Office
450 Brookline Ave
Yawkey 1255
Boston, MA 02215
Phone+1 617-632-3800

Fax+1 617-632-1930
Is this information wrong?

Education & Training

University of Pennsylvania Health SystemFellowship, Hematology and Medical Oncology, 1989 - 1993
University of Pennsylvania Health SystemResidency, Internal Medicine, 1986 - 1989
Case Western Reserve University School of MedicineClass of 1986

Certifications & Licensure

MA State Medical License 2007 - 2024
OH State Medical License 1993 - 2010
CT State Medical License 2005 - 2009
PA State Medical License 1987 - 2006
American Board of Internal Medicine Internal Medicine

Awards, Honors, & Recognition

America's Top Doctors for Cancer Castle Connolly, 2016
Fellow (FACP) American College of Physicians, 2005
Super Doctor SuperDoctors.com

Clinical Trials

SU5416 and Doxorubicin in Treating Patients With Stage IIIB or Stage IV Inflammatory Breast Cancer Start of enrollment: 2000 Apr 01
Completed
Phase 1
Combination Chemotherapy in Treating Patients With Advanced Solid Tumors Start of enrollment: 2000 Feb 01
Completed
Phase 1
HER-2 Protein Vaccine in Treating Women With Breast Cancer Start of enrollment: 2003 Jul 01
Completed
Phase 1
Docetaxel, Doxorubicin, and Cyclophosphamide in Treating Women With Advanced Breast Cancer Start of enrollment: 2003 Sep 01
Withdrawn
Phase 1
Vaccination With Autologous Breast Cancer Cells Engineered to Secrete Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Metastatic Breast Cancer Patients Start of enrollment: 2006 Jan 01
Completed
Phase 1
Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery Start of enrollment: 2009 May 15
Active, not recruiting
Phase 2
Autologous Vaccination With Lethally Irradiated, Autologous Breast Cancer Cells Engineered to Secrete GM-CSF in Women With Operable Breast Cancer Start of enrollment: 2006 Jan 01
Completed
Phase 1
Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa Start of enrollment: 2013 Aug 01
Active, not recruiting
Phase 2
Ruxolitinib W/ Preop Chemo For Triple Negative Inflammatory Brca Start of enrollment: 2014 Feb 01
Completed
Phase 1, Phase 2
A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer Start of enrollment: 2016 Feb 26
Active, not recruiting
Phase 2
A Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Paclitaxel in Patients With Advanced or Metastatic Solid Tumors Start of enrollment: 2018 Oct 25
Completed
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

Clinical outcomes after 1 versus 2-3 lines of neoadjuvant therapy in stage III inflammatory breast cancer.
Faina Nakhlis, Samuel M Niman, Naoto T Ueno, Elizabeth Troll, Sean Ryan, Eren Yeh, Laura Warren, Jennifer Bellon, Beth Harrison, Toshiaki Iwase, H T Carisa Le-Petross,...> ;Breast Cancer Research and Treatment. 2024 Apr 1
Exemestane plus everolimus and palbociclib in metastatic breast cancer: clinical response and genomic/transcriptomic determinants of resistance in a phase I/II trial.
Jorge Gómez Tejeda Zañudo, Romualdo Barroso-Sousa, Esha Jain, Qingchun Jin, Tianyu Li, Jorge E Buendia-Buendia, Alyssa Pereslete, Daniel L Abravanel, Arlindo R Ferreir...> ;Nature Communications. 2024 Mar 19
Activity and safety of enobosarm, a novel, oral, selective androgen receptor modulator, in androgen receptor-positive, oestrogen receptor-positive, and HER2-negative a...
Carlo Palmieri, Hannah Linden, Stephen N Birrell, Sally Wheelwright, Elgene Lim, Lee S Schwartzberg, Amy R Dwyer, Theresa E Hickey, Hope S Rugo, Patrick Cobb, Joyce A ...> ;The Lancet. Oncology. 2024 Mar 1
TBCRC 039: a phase II study of preoperative ruxolitinib with or without paclitaxel for triple-negative inflammatory breast cancer.
Filipa Lynce, Laura E Stevens, Zheqi Li, Jane E Brock, Anushree Gulvady, Ying Huang, Faina Nakhlis, Ashka Patel, Jeremy M Force, Tufia C Haddad, Naoto Ueno, Vered Stea...> ;Breast Cancer Research. 2024 Jan 31
Abnormal vascular structure and function within brain metastases is linked to pembrolizumab resistance.
Kim, A., Lou, K., Giobbie-Hurder, A., Chang, K., Gidwani, M., Hoebel, K., Patel, J., Cleveland, M., Singh, P., Bridge, C., Ahmed, S., Bearce, B., Liu, W., Fuster-Garci...> ;Neuro-Oncology. 2023 Dec 9
Report on the PET/CT Image-Based Radiation Dosimetry of [F]FDHT in Women, a Validated Imaging Agent with New Applications for Evaluation of Androgen Receptor Status in...
Keisha C McCall, Mofei Liu, Su-Chun Cheng, Amanda Abbott, Shipra Dubey, Diane Young, Mayzie Johnston, Annick D Van den Abbeele, Beth Overmoyer, Heather Jacene> ;Journal of Nuclear Medicine Technology. 2023 Sep 1
5 citations
Pembrolizumab in brain metastases of diverse histologies: phase 2 trial results.
Priscilla K Brastianos, Albert E Kim, Anita Giobbie-Hurder, Eudocia Q Lee, Nancy U Lin, Beth Overmoyer, Patrick Y Wen, Lakshmi Nayak, Justine V Cohen, Jorg Dietrich, A...> ;Nature Medicine. 2023 Jul 1
Clinical outcomes of de novo metastatic HER2-positive inflammatory breast cancer.
Ana C Garrido-Castro, Meredith M Regan, Samuel M Niman, Faina Nakhlis, Claire Remolano, Jennifer M Rosenbluth, Caroline Block, Laura E Warren, Jennifer R Bellon, Eren ...> ;NPJ Breast Cancer. 2023 Jun 2
Copy Number Variation in Inflammatory Breast Cancer.
Aditi Hazra, Andrea O'Hara, Kornelia Polyak, Faina Nakhlis, Beth T Harrison, Antonio Giordano, Beth Overmoyer, Filipa Lynce> ;Cells. 2023 Apr 4
13 citations
JAK-STAT Signaling in Inflammatory Breast Cancer Enables Chemotherapy-Resistant Cell States.
Laura E Stevens, Guillermo Peluffo, Xintao Qiu, Daniel Temko, Anne Fassl, Zheqi Li, Anne Trinh, Marco Seehawer, Bojana Jovanović, Maša Alečković, Callahan M Wilde, Ren...> ;Cancer Research. 2023 Jan 18
4 citations
Incidence, characteristics, and management of central nervous system metastases in patients with inflammatory breast cancer.
Laura E G Warren, Samuel M Niman, Marie C Remolano, Jean M Landry, Faina Nakhlis, Jennifer R Bellon, Ayal A Aizer, Nancy U Lin, Sara M Tolaney, Meredith M Regan, Beth ...> ;Cancer. 2022 Dec 1
9 citations
HER2-low inflammatory breast cancer: Clinicopathologic features and prognostic implications.
Tarantino, P., Niman, S., Erick, T., Priedigkeit, N., Harrison, B., Giordano, A., Nakhlis, F., Bellon, J., Parker, T., Strauss, S., Jin, Q., King, T., Overmoyer, B., C...> ;European Journal of Cancer. 2022 Oct 1
8 citations
Phase Ib study of pembrolizumab in combination with trastuzumab emtansine for metastatic HER2-positive breast cancer.
Adrienne G Waks, Tanya E Keenan, Tianyu Li, Nabihah Tayob, Gerburg M Wulf, Edward T Richardson 3rd, Victoria Attaya, Leilani Anderson, Elizabeth A Mittendorf, Beth Ove...> ;Journal for Immunotherapy of Cancer. 2022 Oct 1
8 citations
The feasibility of using an autologous GM-CSF-secreting breast cancer vaccine to induce immunity in patients with stage II-III and metastatic breast cancers.
Karen S Anderson, Timothy K Erick, Meixuan Chen, Heather Daley, Margaret Campbell, Yolonda Colson, Martin Mihm, Labib R Zakka, Marika Hopper, William Barry, Eric P Win...> ;Breast Cancer Research and Treatment. 2022 Jul 1
2 citations
Correction to: Inflammatory breast cancer defined: proposed common diagnostic criteria to guide treatment and research.
R Jagsi, G Mason, B A Overmoyer, W A Woodward, S Badve, R J Schneider, J E Lang, M Alpaugh, K P Williams, D Vaught, A Smith, K Smith, K D Miller> ;Breast Cancer Research and Treatment. 2022 Apr 1
11 citations
Inflammatory breast cancer defined: proposed common diagnostic criteria to guide treatment and research.
R Jagsi, G Mason, B A Overmoyer, W A Woodward, S Badve, R J Schneider, J E Lang, M Alpaugh, K P Williams, D Vaught, A Smith, K Smith, K D Miller> ;Breast Cancer Research and Treatment. 2022 Apr 1
3 citations
Early on-treatment transcriptional profiling as a tool for improving pathological response prediction in HER2-positive inflammatory breast cancer.
Sonia Pernas, Jennifer L Guerriero, Sergey Naumenko, Shom Goel, Meredith M Regan, Jiani Hu, Beth T Harrison, Filipa Lynce, Nancy U Lin, Ann Partridge, Aki Morikawa, Jo...> ;Therapeutic Advances in Medical Oncology. 2022 Jan 1
35 citations
Phase II study of ipilimumab and nivolumab in leptomeningeal carcinomatosis.
Priscilla K. Brastianos, Matthew R. Strickland, Eudocia Q. Lee, Nancy Wang, Justine V. Cohen, Ugonma Chukwueke, Deborah Forst, April F. Eichler, Beth Overmoyer, Nan Li...> ;Nature Communications. 2021 Oct 12
1 citations
MRI Changes in Breast Skin Following Preoperative Therapy for Patients with Inflammatory Breast Cancer.
Eren D. Yeh, Anna Rives, Faina Nakhlis, Camden P. Bay, Beth T. Harrison, Jennifer R. Bellon, Marie Claire Remolano, Heather A. Jacene, Catherine S. Giess, Beth Overmoyer> ;Academic Radiology. 2021 Sep 21
16 citations
Nivolumab in combination with cabozantinib for metastatic triple-negative breast cancer: a phase II and biomarker study.
Romualdo Barroso-Sousa, Tanya Keenan, Tianyu Li, Nabihah Tayob, Lorenzo Trippa, Ricardo G. Pastorello, Edward T. Richardson, Deborah A. Dillon, Zohreh Amoozgar, Beth O...> ;NPJ Breast Cancer. 2021 Aug 25
10 citations
Phase II trial of veliparib and temozolomide in metastatic breast cancer patients with and without BRCA1/2 mutations.
Jing Xu, Tanya Keenan, Beth Overmoyer, Nadine Tung, Rebecca Gelman, Karleen Habin, Judy Garber, Leif W. Ellisen, Eric P. Winer, Paul E. Goss, Beow Y. Yeap, Bruce A. Ch...> ;Breast Cancer Research and Treatment. 2021 Aug 20
6 citations
Inflammatory breast cancer appearance at presentation is associated with overall survival
Wintana Balema, Diane Liu, Yu Shen, Randa El-Zein, Bisrat G. Debeb, Megumi Kai, Beth Overmoyer, Kathy D. Miller, Huong T. Le-Petross, Naoto T. Ueno, Wendy A. Woodward> ;Cancer Medicine. 2021 Jul 30
2 citations
Dermal Lymphatic Invasion, Survival, and Time to Recurrence or Progression in Inflammatory Breast Cancer.
Kelly A. Hirko, Meredith M. Regan, Marie Claire Remolano, Julia Schlossman, Beth T. Harrison, Eren D. Yeh, Heather A. Jacene, Faina Nakhlis, Caroline Block, Jennifer M...> ;American Journal of Clinical Oncology. 2021 Jun 21
10 citations
Imaging Androgen Receptors in Breast Cancer with 18 F-fluoro-5α-dihydrotestosterone-PET: A Pilot Study.
Heather A. Jacene, Mofei Liu, Su-Chun Cheng, Amanda Abbott, Shipra Dubey, Keisha C. McCall, Diane Young, Mayzie Johnston, Annick D. Van den Abbeele, Beth Overmoyer> ;Journal of Nuclear Medicine. 2021 May 28
Phase II and Biomarker Study of Cabozantinib in Metastatic Triple-Negative Breast Cancer Patients.
Sara M Tolaney, David R Ziehr, Hao Guo, Mei R Ng, William T Barry, Michaela J Higgins, Steven J Isakoff, Jane E Brock, Elena V Ivanova, Cloud P Paweletz, Michelle K De...> ;The Oncologist. 2021 Aug 1
Join now to see all

Journal Articles

Effect of Eribulin with or Without Pembrolizumab on Progression-Free Survival for Patients with Hormone Receptor–Positive, ERBB2-Negative Metastatic Breast Cancer
Sara M Tolaney, Gerburg Wulf, Laura Spring, Beth Overmoyer, Ann H Partridge, Eric P Winer, Ian E Krop, JAMA Oncology
A Pharmacogenetic Prediction Model of Progression‐Free Survival in Breast Cancer Using Genome‐Wide Genotyping Data from CALGB 40502 (Alliance)
Hope S Rugo, Francisco Castillos, Beth Overmoyer, Mark J Ratain, Clinical Pharmacology & Therapeutics

Press Mentions

Breast Cancer: Common, Deadly and Preventable?October 25th, 2022
Enobosarm Shows Clinical Benefit in AR+, ER+ Metastatic Breast CancerJanuary 9th, 2021
Veru Expands Oncology Drug Pipeline; Exclusively Licenses Phase 3 Clinical Stage Targeted Therapy for Endocrine Resistant Metastatic Breast CancerDecember 9th, 2020
Join now to see all

Grant Support

SU5416 And Doxorubicin In Inflammatory Breast CancerNational Center For Research Resources2004
Pegylated Liposomal Doxorubicin + Vinorelbine + Gemcitabine For Solid TumorsNational Center For Research Resources2004
Fenretinide + Paclitaxel + Cisplatin For Advanced Solid TumorsNational Center For Research Resources2004
Bevacizumab And Docetaxel For Locally Advanced Breast CancerNational Center For Research Resources2004
Translational Research In Breast CancerNational Cancer Institute2000–2004
Core--Clinical Trials FacilityNational Cancer Institute2001–2002